DERIVATIVE LIABILITIES (Details) - USD ($) |
6 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2022 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Derivative Liabilities [Line Items] | ||||
| Conversion of Stock, Shares Converted (in Shares) | 4,619 | |||
| Sale of stock, percentage of ownership | 19.90% | |||
| Milestone Payment | $ 10,000,000 | |||
| Redemption term. | For the period ending upon the earlier of (i) 10 years after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to 3.5% of the Company’s net sales (the “Royalty”) on a quarterly basis, where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine. | |||
| Royalty percentage | 3.50% | |||
| (Loss) on change in fair value of derivative liabilities | $ (10,232) | $ (135,342) | ||
| Valuation of contingent milestone payment, discount rate | 14.00% | 12.49% | ||
| Series A Non-Voting Convertible Preferred Stock [Member] | ||||
| Derivative Liabilities [Line Items] | ||||
| Designated shares (in Shares) | 80,965 | 80,965 | ||